Production of $p$-amino-$\text{-}$phenylalanine ($\text{l}$-PAPA) from glycerol by metabolic grafting of Escherichia coli

Behrouz Mohammadi Nargesi, Natalie Trachtmann, Georg A. Sprenger and Jung-Won Youn*

Abstract

Background: The non-proteinogenic aromatic amino acid, $p$-amino-$\text{l}$-phenylalanine ($\text{l}$-PAPA) is a high-value product with a broad field of applications. In nature, $\text{l}$-PAPA occurs as an intermediate of the chloramphenicol biosynthesis pathway in Streptomyces venezuelae. Here we demonstrate that the model organism Escherichia coli can be transformed with metabolic grafting approaches to result in an improved $\text{l}$-PAPA producing strain.

Results: Escherichia coli K-12 cells were genetically engineered for the production of $\text{l}$-PAPA from glycerol as main carbon source. To do so, genes for a 4-amino-4-deoxychorismate synthase ($\text{pabAB}$ from Corynebacterium glutamicum), and genes encoding a 4-amino-4-deoxychorismate mutase and a 4-amino-4-deoxyprephenate dehydrogenase ($\text{papB}$ and $\text{papC}$, both from Streptomyces venezuelae) were cloned and expressed in E. coli W3110 (lab strain LJ110). In shake flask cultures with minimal medium this led to the formation of ca. 43±2 mg l$^{-1}$ of $\text{l}$-PAPA from 5 g l$^{-1}$ glycerol. By expression of additional chromosomal copies of the $\text{tktA}$ and $\text{glpX}$ genes, and of plasmid-borne $\text{aroFBL}$ genes in a tyrR deletion strain, an improved $\text{l}$-PAPA producer was obtained which gave a titer of 5.47±0.4 g l$^{-1}$ $\text{l}$-PAPA from 33.3 g l$^{-1}$ glycerol (0.16 g $\text{l}$-PAPA/g of glycerol) in fed-batch cultivation (shake flasks). Finally, in a fed-batch fermenter cultivation, a titer of 16.7 g l$^{-1}$ $\text{l}$-PAPA was obtained which is the highest so far reported value for this non-proteinogenic amino acid.

Conclusion: Here we show that E. coli is a suitable chassis strain for $\text{l}$-PAPA production. Modifying the flux to the product and improved supply of precursor, by additional gene copies of $\text{glpX}$, $\text{tkt}$ and $\text{aroFBL}$ together with the deletion of the $\text{tyrR}$ gene, increased the yield and titer.

Keywords: Escherichia coli, Non-proteinogenic aromatic amino acids, $p$-Amino-$\text{l}$-phenylalanine, Metabolic grafting
chloramphenicol and pristinamycin biosynthesis pathways (as dietary supplement in the treatment of phenylketonuria, and medicine). L-Phe is mainly used for the synthesis of the low-calorie sweetener aspartame (l-aspartyl-l-phenylalanine methyl ester) while L-Trp is used as dietary supplement in the treatment of phenylketonuria. It is also the precursor in the synthesis of Levodopa (l-3,4-dihydroxyphenylalanine) which is used to treat Parkinson’s disease [19]. Ubiquinone-10 (Q10), folic acid, and vitamin K (plastoquinone) are used as nutritional additives [20, 21].

The rare, non-proteinogenic aromatic amino acid, para-amino-l-phenylalanine (l-PAPA) is used for technical and pharmaceutical applications [22–25] and has been described as a building block of the anticancer drug, Melphalan® [26, 27]. In nature, l-PAPA occurs in plant seeds (Vigna vexillata; [28]), and is an intermediate of the chloramphenicol and pristinamycin biosynthesis pathways in Streptomyces venezuelae and S. pristinaespiralis [29–31]. L-PAPA is also a precursor of the antibiotic ofafloxin β-lactone of Pseudomonas fluorescens [32] and of GameXPeptides in the entomopathogenic bacterium, Photorhabdus luminescens [33]. L-PAPA was moreover successfully used as precursor in the biosynthetic diversification of jadomycin production with S. venezuelae cells [34]. L-PAPA has also been used for the synthesis of the biopolyamide precursor, 4-aminohydrocinnamic acid [35, 36].

L-PAPA synthesis starts from chorismate which is first converted by a glutamine- or ammonia-dependent 4-amino-4-deoxychorismate synthase to give 4-amino-4-deoxychorismate (ADC) [37]. This step is common to both, the para-aminobenzoate (PABA) and the chloramphenicol/pristinamycin biosynthesis pathways. In PABA biosynthesis, ADC synthase is encoded by genes papA and papB—which are not organized in an operon—in E. coli [38]. In Corynebacteria, these genes are fused as papAB such as in C. glutamicum [39–41], in C. efficiens [42], or C. callunae [40]. In pristinamycin biosynthesis, the pathway-specific gene is named papA in S. pristinaespiralis [30], and in chloramphenicol biosynthesis of S. venezuelae it is either termed papA [43] or cmI/b [44], respectively. Despite the different nomenclature, these genes display high sequence identities [30, 43–45]. ADC is converted by 4-amino-4-deoxy-chorismate mutase (gene papB in S. pristinaespiralis; alternatively cmId in S. venezuelae) and 4-amino-4-deoxyphenylalanine dehydrogenase (papC and cmLC, respectively) to yield p-aminophenylpyruvate (PAPP; [30, 43, 44]). By transamination, l-PAPA is formed and serves then as intermediate for the production of several antibiotics. Recently, papA,B,C homolog genes from Pseudomonas fluorescens have been successfully cloned and expressed in E. coli [24].

Escherichia coli is not a natural producer of l-PAPA but the E. coli aminotransferases TyrB and AspC are known to convert PAPP into l-PAPA (Fig. 1) [46, 47]. Earlier, l-PAPA formation in recombinant E. coli (carrying papABC genes from S. venezuelae on a low-copy plasmid) had been shown by the group of Schultz [43]. They used this in vivo produced compound as “21st proteinogenic amino acid” together with a modified tyrosyl-tRNA synthetase and a mutant tyrosine amber suppressor tRNA in specifically engineered E. coli strains. While formation of up to 0.7 mM of intracellular l-PAPA were measured in these recombinant cells, no data on extracellular production were provided [43], however.

---

**Fig. 1** Overview of the de novo l-PAPA biosynthesis pathway from glycerol in E. coli. The scheme of reactions is modified from Gottlieb et al. [15]. Broken arrows indicate incomplete presentation of the metabolic pathway. AroF DAHP synthase, AroB dehydroquinate synthase, AroL shikimate kinase, AspC aspartate transaminase, GlpD glycerol-3-phosphate dehydrogenase, GlpF glycerol facilitator, GlpK glycerol kinase, GlpX fructose-1,6-bisphosphate phosphatase, PabAB 4-amino-4-deoxychorismate synthase, PapB 4-amino-4-deoxychorismate mutase, PapC 4-amino-4-deoxyphenylalanine dehydrogenase, TktA transketolase A, and TyrB aromatic aminotransferase is presented.
A preferred carbon source for the production of aromatic amino acids with *E. coli* is glucose. Glycerol which can be used as an alternative carbon and energy source by *E. coli*, is especially attractive for the production of aromatic amino acids [15, 18, 48]. Glycerol can be taken up in *E. coli* either via the glycerol facilitator, GlpF or by unassisted diffusion [49]. After phosphorylation by the ATP-dependent glycerol kinase (GlpK; [50]), and an oxidation step by glycerol 3-phosphate dehydrogenase (GlpD; [51]) dihydroxyacetone phosphate (DHAP) can enter the lower glycolysis. Glycerol has no competing application in the food industry and it appears as a byproduct during biodiesel production [52]. Here we describe the construction of *E. coli* strains for the production of valuable l-PAPA using glycerol as sole carbon and energy source.

**Results**

Construction of a de novo l-PAPA biosynthesis pathway in *E. coli*

As l-PAPA is a non-proteinogenic amino acid for wildtype *E. coli* cells, we wanted to know first whether it shows any inhibitory or toxic effects on growth. Therefore, cells of *E. coli* K-12 wildtype strain L1110 (W3110) were grown in minimal media with glycerol as sole carbon source and synthetic l-PAPA was added at varying concentrations. As can be seen in Fig. 2, the growth rate in the presence of 4 or 8 mM l-PAPA was slightly reduced (μ = 0.43 h⁻¹ and μ = 0.39 h⁻¹, respectively) when compared to growth in the absence of l-PAPA (μ = 0.47 h⁻¹); however, very similar final optical densities (OD₆₀₀ values) were reached after 24 h of incubation. At a concentration of 33 mM l-PAPA (5.9 g l⁻¹), however, the formation of biomass was impaired and the growth rate was conceivably reduced to μ = 0.24 h⁻¹. Thus we reasoned that l-PAPA production in recombinant *E. coli* strains could be proceeded without serious toxicity problems caused by the novel product.

We decided to establish a synthetic pathway leading to l-PAPA by construction of a strain which carries the genes from different donor organisms (“metabolic grafting”). From previous work in our group [2, 41], the gene encoding 4-amino-4-deoxychorismate synthase from the PABA biosynthesis route of *C. glutamicum* (pabAB<sub>Gl</sub>) was available in recombinant form and under the control of an IPTG-inducible Ptac promoter on plasmid pC53 (see Table 1). We preferred the pabAB<sub>Gl</sub> gene over the two separate genes pabA and pabB which reside in the *E. coli* chromosome, as the plasmid-borne combination of the latter genes had shown less active enzyme [41]. To complete the intended l-PAPA pathway, genes papB and papC were added. PapB and papC were custom-synthesized based upon the gene sequences of *S. venezuela* (pabB, 4-amino-4-deoxy-chorismate mutase; papC, 4-amino-4-deoxyprephenate dehydrogenase) and codon optimized for expression in *E. coli* (GeneOptimizer, Thermo Fisher/GeneArt, Regensburg, Germany). The two genes were then cloned together as a cassette with pabAB<sub>Gl</sub> to yield plasmid pC53BC (see Table 1, Additional file 1: Figure S4).

**L-PAPA production by recombinant *E. coli* strains**

Expression of the gene cassette from pC53BC was first studied in the background of the wildtype strain *E. coli* L1110. Cells were cultivated in shake flasks in minimal medium with glycerol (5 g l⁻¹) and induction was by addition of IPTG (0.5 mM final concentration). This already led to l-PAPA accumulation of about 43 ± 2 mg l⁻¹ in the supernatant whereas no l-PAPA was detected in the control strain (see Table 2). This proved that l-PAPA can be formed in conceivable amounts by *E. coli* cells and is in line with former observations with *E. coli* strains that were constructed in different manners [24, 43].

It is well-known that overexpression of the *aroF, aroB,* and *aroL* genes enhances formation of chorismate-derived compounds [3, 15, 59]. We therefore analyzed the effect of plasmid-borne overexpression of the genes *aroF* (DAHP synthase), *aroB* (dehydroquinate synthase) and *aroL* (shikimate kinase) present as a cassette on a second vector (pJN522; Kan<sup>R</sup>, see Table 1 and Additional file 1: Figure S1) which is compatible with pC53BC. The additional IPTG-induced expression of *aroFBL* doubled the product titer after 48 h to 86.6 ± 3.7 mg l⁻¹ (Table 2), most likely due to an improved provision of shikimate precursors for l-PAPA formation.

![Fig. 2](image-url) Growth of *E. coli* L1110 in minimal media with glycerol and different l-PAPA concentrations. The cells were cultivated at 37 °C in the absence of l-PAPA (circles), or in the presence of 4 mM (squares), 8 mM (triangles), or 33 mM of l-PAPA (diamonds), respectively. Cultivations were performed twice and the mean values are given.
Next, to avoid an undesired loss of chorismate to L-Phe and L-Tyr formation (Fig. 1), a pheA-tyrA-aroF deletion mutant of LJ110 was used as host strain. This strain (FUS 4) is a double auxotroph for L-Phe and L-Tyr; it had been successfully used previously for the production of L-Phe; in addition, strain FUS4 carries a chromosomally inserted copy of the aroFBL cassette [15]. This second generation strain showed improved L-PAPA formation in shake flasks (minimal media with glycerol and growth supplementation by L-Phe and L-Tyr; see Table 3). The L-PAPA titer was raised to about 200 mg l⁻¹ with a yield of ca. 0.04 g L-PAPA/g of glycerol compared to FUS 4 with the same plasmid combination in FUS 4.7 led to strain FUS4.7R. When transformed with plasmids pC53BC and pJNT-aroFBL this combination resulted in a slightly increased titer of L-PAPA (534 ± 24 mg l⁻¹) and a yield of ca. 11% L-PAPA/glycerol

| Strains | Characteristics | Reference/origin |
|---------|-----------------|------------------|
| E. coli DH5α | φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 gyrA96 relA1 | Invitrogen |
| E. coli LJ110 | Wildtype W3110 (F−, λ−, IN (rrnD-rrnE), rph-1) | [53] |
| E. coli FUS 4 | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | [15] |
| E. coli FUS 4.7 | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | [15] |
| E. coli FUS4.7R | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | This study |
| Strains Characteristics Reference/origin |
| E. coli DH5α | φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 gyrA96 relA1 | Invitrogen |
| E. coli LJ110 | Wildtype W3110 (F−, λ−, IN (rrnD-rrnE), rph-1) | [53] |
| E. coli FUS 4 | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | [15] |
| E. coli FUS 4.7 | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | [15] |
| E. coli FUS4.7R | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | This study |
| Plasmids | | |
| pJNT522 | P lacc RBS, KanR | This study, see Additional file 1 |
| pJNT-aroFBL | P laccaroFBL, arobl, arorl, KanR | This study |
| pJF119EH | P lacc RBS, Amp,R, lac | [54] |
| pC53 | pJF119EH, P lacc pabAB, Amp,R, lac | [41] |
| pC53BC | pJF119EH, P lacc pabAB, papBC, Amp,R, lac | This study |
| pMK-papBC | Cloning vector including the codon optimized genes of papBC, KanR | Thermo Fisher (GeneArt) custom synthesis |
| pKD46 | λ Red disruption system (γβ, eks under control of PapuBC, Amp,R) | [55] |
| pCP20 | FLP+, λCIS3+, λ, PR Rep,Amp,R, CmR | [56] |
| pCAS30-FRT-crt-FRT | pJF1190N, P. ananatis cte gene, FRT-sites, Amp,R, CmR, source of cte-gene cassette | [57] |
| plieM2 | rhaR rhaS rhaPBAD, eGFP, mob KanR | [58] |

Next, to avoid an undesired loss of chorismate to L-Phe and L-Tyr formation (Fig. 1), a pheA-tyrA-aroF deletion mutant of LJ110 was used as host strain. This strain (FUS 4) is a double auxotroph for L-Phe and L-Tyr; it had been successfully used previously for the production of L-Phe; in addition, strain FUS4 carries a chromosomally inserted copy of the aroFBL cassette [15]. This second generation strain showed improved L-PAPA formation in shake flasks (minimal media with glycerol and growth supplementation by L-Phe and L-Tyr; see Table 3). The L-PAPA titer was raised to about 200 mg l⁻¹ with a yield of ca. 0.04 g L-PAPA/g of glycerol compared to E. coli LJ110 (Table 2).

**Escherichia coli** FUS4.7, a FUS4 derivative which has additional chromosomal copies of tktA (transketolase A) and glpX (fructose 1,6-bisphosphate phosphatase), respectively, had turned up as an improved L-Phe producer before [15]. It was therefore used as recipient for pC53BC and pJNT-aroFBL to study its L-PAPA productivity. Indeed, the titer further increased to 449 ± 29 mg l⁻¹ and the yield was more than double in comparison to FUS 4 with the same plasmid combination (see Table 3).

Finally, the gene for the transcriptional regulator, tyrR [60], was deleted. Such a deletion had been shown to confer a positive effect for aromatic compound production in engineered E. coli strains [61–66]. Deletion of tyrR in FUS 4.7 led to strain FUS4.7R. When transformed with plasmids pC53BC and pJNT-aroFBL this combination resulted in a slightly increased titer of L-PAPA (534 ± 24 mg l⁻¹) and a yield of ca. 11% L-PAPA/glycerol

**Table 1** List of *E. coli* strains, plasmids and oligonucleotides

| Strains | Characteristics | Reference/origin |
|---------|-----------------|------------------|
| E. coli DH5α | φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 gyrA96 relA1 | Invitrogen |
| E. coli LJ110 | Wildtype W3110 (F−, λ−, IN (rrnD-rrnE), rph-1) | [53] |
| E. coli FUS 4 | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | [15] |
| E. coli FUS4.7 | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | [15] |
| E. coli FUS4.7R | Δ(pheA-tyrA-aroF) Δlac P laccaroFBL+ | This study |

**Table 2** Formation of L-PAPA in *E. coli* wild-type strain with different plasmid combinations

| Plasmid combination | Final OD (600 nm) | Yield l-PAPA/ glycerol (g g⁻¹) | Final l-PAPA titer (mg l⁻¹) |
|---------------------|-----------------|-----------------------------|-----------------------------|
| pJF119EH/ pJNT522 | 5.89 ± 0.35 | 0 | 0 |
| pC53BC/pJNT522 | 5.01 ± 0.95 | 0.01 | 43.2 ± 2 |
| pC53BC/pJNT-aroFBL | 4.75 ± 0.85 | 0.02 | 86.6 ± 4 |

*E. coli* LJ110 wild-type strain was transformed with two different and compatible IPTG-inducible plasmids (control plasmids pJF119EH and pJNT522) to study the effects of the presence of pabAB, papBC, and aroFBL genes, respectively. pC53BC carries pabAB and papBC as a gene cassette under the control of a Ptac promoter. To study the effect of enhanced flux through the aromatic pathway, aroFBL were cloned onto pJNT522 plasmid. Biomass yields after 48 h of cultivation in minimal media with 5 g l⁻¹ glycerol are shown as OD₆₀₀ values. The cultivations were performed in triplicate and mean values and standard deviations are given.
Table 3 Comparison of l-PAPA yields in next generation strains

| E. coli strains | Final OD (600 nm) | Yield l-PAPA/glycerol (g g⁻¹) | Final l-PAPA titer (mg l⁻¹) |
|----------------|------------------|-------------------------------|---------------------------|
| FUS 4/pC53BC/pJNT-aroFBL | 3.77 ± 0.25 | 0.04 | 202.7 ± 4.5 |
| FUS 4.7/pC53BC/pJNT-aroFBL | 3.66 ± 0.13 | 0.09 | 449.4 ± 29.4 |
| FUS 4.7R/pC53BC/pJNT-aroFBL | 3.86 ± 0.14 | 0.11 | 534.1 ± 24.1 |

Double auxotroph strains carrying two plasmids (pC53BC and pJNT-aroFBL) were grown in shake flasks in minimal media with 5 g l⁻¹ glycerol and supplemented by l-Phe and l-Tyr (0.04 g l⁻¹ each) and appropriate antibiotics. Induction with IPTG (0.5 mM final concentration) was at OD₆₀₀ of ca. 0.6 and strains were further incubated until a total cultivation time of 48 h. The cultures were performed in triplicate and mean values and standard deviations are given.

Fed-batch shake flask cultivation with E. coli FUS4.7R/pC53BC/pJNT-aroFBL

These encouraging results from shake flask cultivations prompted us to study growth behavior and l-PAPA production in fed-batch condition. We chose the best producer, so far, E. coli FUS4.7R/pC53BC/pJNT-aroFBL. After pre-incubation and appropriate IPTG induction in shake flask with a starting concentration of 5 g l⁻¹ of glycerol at 37 °C, temperature was lowered to 30 °C and glycerol (~5 g l⁻¹) was added in intervals of 12 h. To roughly adjust for the pH, sodium bicarbonate was added (30 mM) every 24 h, as well as 15 mM ammonium sulfate as a nitrogen source to allow formation of l-PAPA. As a result, a total of 33.3 g l⁻¹ glycerol was consumed in 134 h of cultivation (Fig. 3) and a titer of 5.47 ± 0.41 g l⁻¹ of l-PAPA was detected in the supernatant; this corresponds to a yield of 16% l-PAPA/glycerol (g g⁻¹).

Fed-batch fermentation in a bioreactor

In order to scale up l-PAPA production under controlled conditions, we cultivated E. coli FUS4.7R/pC53BC/pJNT-aroFBL cells in an aerated, pH-controlled 30 l stirred-tank reactor with minimal medium and glycerol as sole carbon source. The starting volume for the batch was 8 l and the final volume (after fed-batch) of 12.25 l. Details of the fermentation procedure are given in the Materials and Methods section. The feeding started after the initially added glycerol (8.1 g l⁻¹) was consumed. Glycerol was then fed to maintain a concentration between 0.6 and 1.0 g l⁻¹. Additionally, l-Phe and l-Tyr were added in two pulses to allow biomass formation. After 77 h, a final cell dry weight of 21.6 g l⁻¹ was reached and 131.7 g l⁻¹ of glycerol had been consumed (see Fig. 4). A total concentration of 16.78 g l⁻¹ l-PAPA was produced by then. This equals a yield of 0.13 l-PAPA/glycerol (g g⁻¹) and a space–time-yield of l-PAPA formation over the whole process of 0.22 g l⁻¹ h⁻¹. The total amount of l-PAPA produced during the 77 h of fermentation was 205 g. The produced l-PAPA was analyzed by MS and the obtained mass was in excellent agreement with the commercially available l-PAPA (Additional file 2).

To our knowledge, this is the highest l-PAPA titer which has been reached with E. coli cells.

Discussion

Expansion of the chorismate pathway of E. coli to produce a variety of non-standard aromatic compounds has already been very successful in many cases. Pioneering work has been done by the group of Frost and others already in the 1990s [61–64, 66]. Thereafter, processes have been published for p-hydroxybenzoic acid [61, 65], p-aminobenzoic acid [40, 42], protocatechuic acid and catechol [65], vanillin [67, 68], anthranilic acid [69], δ-tocotrienol (a vitamin E compound, [70]), phenol [71–74], salicylic acid and muconic acid [5, 75], 3,4-dihydroxybenzoic acid [40], protocatechuic acid and catechol [65], vanillin [67, 68], anthranilic acid [69], δ-tocotrienol (a vitamin E compound, [70]), phenol [71–74], salicylic acid and muconic acid [5, 75], styrene, cinnamic acid and hydroxylated derivatives thereof [7, 76–80], tyrosol [81], (hydroxyl)phenyllactic acid, tyramine and other l-Phe- or l-Tyr-derived compounds [76], rosmarinic acid and flavonoids [82, 83], antitumor drugs like violacein and deoxyviolacein [84], several plant alkaloids [85], or even opiates like thebaine, reticuline or hydrocodone [86]. Further examples may be found in recent review articles [79, 87, 88].

Fig. 3 Glycerol fed-batch cultivation of E. coli FUS4.7 R/pC53BC/pJNT-aroFBL in shake flasks. The initial glycerol concentration was 5 g l⁻¹. After 24 h of cultivation the cultures were induced with 0.5 mM IPTG (final concentration) and the shake flasks were transferred from 37 to 30 °C before adding pulses of ~5 g l⁻¹ of glycerol every 12 h. To adjust the pH, sodium bicarbonate (30 mM) was added every 24 h as well as 15 mM of ammonium sulfate. The concentrations of glycerol (empty circles) and l-PAPA (empty squares) were determined by HPLC. OD₆₀₀ values are presented as filled squares. The cultivations were performed in triplicate and the mean values and standard deviations are given.

(g g⁻¹) (Table 3). The biomass yield of the three strains in shake flasks was about the same.
These approaches most often have in common that heterologous genes from other donor organisms and from other biosynthetic pathways are used for transplantation into the genome of recipient strains such as \textit{E. coli}. These recipients often have been engineered for a fortified provision of chorismate from the general aromatic amino acid pathway [61, 66, 69, 89]. We propose to classify this subdivision of “metabolic engineering” [90] as “metabolic grafting” [3] as it may be metaphorically likened to the well-known and centuries old procedure in plant husbandry which is termed “grafting”. Therein, for example, a fledgling twig from a precious fruit tree is merged (pruned) with a robust stem of another tree (which may be of another plant species), resulting in strong fruit bearing by the grafted-upon plant (see for example the case of using North American vine as rootstock for many rare and precious European wines to overcome the \textit{Phylloxera} vine pest in the late nineteenth century [91]). In analogy, the transfer of such a grafting procedure to the expansion of the chorismate pathway in microorganisms thus implies cloning and expression of heterologous genes to allow production of non-standard products. Whereas the proteinogenic aromatic amino acids \( \text{l-Phe, l-Tyr, and l-Trp} \) can be produced by recombinant \textit{E. coli} strains even without the introduction of foreign genes ([3, 89, 92], non-standard and non-proteinogenic aromatic amino acids require such a grafting procedure. Examples are the production of \( \text{l-homophenylalanine by introduction of genes from the cyanobacterium \textit{Nostoc punctiforme} for the chain elongation of l-Phe [93], improved production of l-3,4-dihydroxyphenylalanine (l-DOPA) from \textit{E. coli} grown on glucose [94, 95], or the production of \( \text{D-phenylglycine via phenylpyruvic acid and mandelic acid [96]}. \)

Following the initial work of the Schultz group on \( \text{l-PAPA} \) formation in recombinant \textit{E. coli} strains using the genes \text{papABC} from \textit{S. venezuelae} [43], Takaya and coworkers recently presented a genetically modified \textit{E. coli} to produce \( \text{l-PAPA} \) from glucose by introduction of \text{papABC} genes from \textit{P. fluorescens} [24]. A high titer of 4.4 \( \text{l-PAPA g l}^{-1} \) with a production yield of 17\% (g g\(^{-1}\)) from glucose was achieved in minimal media supplemented with tryptophan (5 g l\(^{-1}\)) and yeast extract (2.5 g l\(^{-1}\)) in a bioreactor [24].

The aim of the present study was to produce the high value compound \( \text{l-PAPA} \) with genetically engineered \textit{E. coli} strains from glycerol, a renewable carbon source (for a recent review see [48]). Glycerol has become a favorable carbon source as it is a byproduct of biodiesel production [15, 48, 52, 97]. The advantage to use glycerol instead of glucose is that there is no need of stoichiometric amounts of phosphoenolpyruvate (PEP) for its uptake into \textit{E. coli} cells, whereas the PTS-dependent glucose uptake needs PEP [98]. PEP and E4P are important precursors of the initial reaction of shikimate pathway to form DAHP by the DAHP synthase [99]. Furthermore, glycerol (a C3 unit), compared to glucose (a C6 unit), has a higher reduction potential per C3 unit which in turn could yield higher biomass and product formation [15, 48, 100–102]. The precursor supply is a pivotal parameter to improve production of compound with origin in the shikimate pathway [17]. Our group had shown in previous studies [15, 18] that the improved supply of E4P by integration of additional gene copies of the fructose 1,6-bisphosphate phosphatase (glpX) and transketolase (tktA) increased the yield for \( \text{l-Phe} \) production [15, 18]. Therefore we applied this knowledge here and found that \( \text{l-PAPA} \) synthesis also profited from these genetic alterations. The extra gene copies in \textit{FUS} 4.7 led to a doubled product titer of about 0.45 \( \pm \) 0.03 g l\(^{-1}\) in batch culture shake flasks after 48 h compared to the parent strain \textit{FUS} 4.0 (0.20 \( \pm \) 0.01 g l\(^{-1}\)) in minimal medium with 5 g l\(^{-1}\) glycerol (Table 2).

Moreover, we analyzed the effect of a \text{tyrR} deletion in the recombinant \textit{E. coli} \textit{FUS} 4.7. The transcriptional regulon of \text{tyrR} is well characterized in \textit{E. coli} [60]. \text{tyrR} downregulates as transcriptional repressor the genes \text{aroF, aroG, aroL, tyrP, aroP, tyrA and tyrB} in the presence of \( \text{l-Tyr} \) [60, 103]. We observed a beneficial effect on \( \text{l-PAPA} \) production by a \text{tyrR} deletion in \textit{E. coli} \textit{FUS} 4.7R compared to \textit{E. coli} \textit{FUS} 4.7. The yield was increased by \( \approx \) 18\% from 0.09 \( \text{l-PAPA/glycerol (g g}^{-1}\)) to 0.11 \( \text{l-PAPA/glycerol (g g}^{-1}\)) in batch cultivation. This result...
is in good agreement with previous studies [76, 92, 94]. It is likely that the positive effect of a tyrR deletion relies on the increased transcriptional expression and resulting increased specific activities for members of the TyrR regulon.

By changing the cultivation condition of E. coli FUS4.7T to a fed-batch cultivation in shake flasks, we improved the total yield to 0.16 l-PAPA/glycerol (g g\(^{-1}\)) and reached a titer of about 5.47 ± 0.41 g l\(^{-1}\) l-PAPA after 134 h. This titer is already higher than the 4.4 g l\(^{-1}\) obtained found by the Takaya group in minimal media with glucose as main C source (plus added tryptone and yeast extract) [24]. However, as the cultivation in fed-batch shake flasks is not optimal in term of oxygen supply and pH stability it may be advantageous to perform the cultivation in a pH- and pO\(_2\)-controlled bioreactor. Indeed, we found that during a run of 77 h, 131.7 g l\(^{-1}\) of glycerol were consumed and a total of 205 g of l-PAPA were produced (16.78 g l\(^{-1}\)). Only small amounts of acetate (<2 g l\(^{-1}\)) and no lactate as by-products were detected during fermentation. This corresponds to a yield of 0.13 g l-PAPA per g of glycerol, slightly lower than in the fed-batch shake flask cultures. The reached titer in the bioreactor showed that l-PAPA production at higher concentration is still feasible although the growth of E. coli L110 was impaired at 5.9 g l\(^{-1}\) (Fig. 2). In comparison with other products of “extended shikimate pathway” [7], the presented data on l-PAPA are in the same range as p-aminobenzoate from glucose in recombinant E. coli (4.8 g l\(^{-1}\) in 48 h; yield of 0.16 g g\(^{-1}\) [79]) but below anthranilate (o-aminobenzoate: 14 g l\(^{-1}\) in 34 h on glucose with a yield of 0.2 g g\(^{-1}\) [69]) where both products, however, need only one ammonium equivalent for their production.

To further improve the E4P precursor supply it can be considered to further increase the number of gene copies in the E. coli genome as only one additional copy of tktA and g1pX was inserted. The enhanced flux through the shikimate pathway by overexpression of plasmid-borne aroFBL genes showed a beneficial effect in our study. Other studies have shown that the overexpression of the other shikimate pathway genes (aroA, C, D and E) as well improved the formation of l-Tyr which is derived from chorismate [14]. It is likely that a positive effect can be also observed for the l-PAPA production. This improved route to l-PAPA based upon a simple medium with a sustainable carbon source which is currently in ample supply from biodiesel production and which does not compete with human nutrition, opens up the possibility to produce an interesting building block in larger scale.

Conclusion

This study demonstrated that E. coli is a good chassis strain for l-PAPA production using glycerol as an alternative sole carbon source. We constructed by metabolic grafting a de novo pathway for l-PAPA in E. coli. By improving the E4P precursor supply and the increased flux through the shikimate pathway both l-PAPA titer and yield were augmented.

Methods

Chemicals, antibiotics, buffer components, culture media and analytical standards, used in this study were purchased from AppliChem GmbH (Darmstadt, Germany), Carl Roth GmbH (Karlsruhe, Germany), or Sigma-Aldrich/Fluka (Taufkirchen, Germany) and were of the highest available purity. l-PAPA was purchased from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany).

Bacterial strains, plasmids and cultivation conditions

All bacterial strains, plasmids, and oligonucleotides used in this study are listed in Table 1. For the cultivation of E. coli, lysogeny broth (LB) was used as complex media [104]. The minimal media (MM) contained 3 g l\(^{-1}\) KH\(_2\)PO\(_4\), 12 g l\(^{-1}\) K\(_2\)HPO\(_4\), 5 g l\(^{-1}\) (NH\(_4\))\(_2\)SO\(_4\), 0.3 g l\(^{-1}\) MgSO\(_4\)·7H\(_2\)O, 0.1 g l\(^{-1}\) NaCl, 0.1125 g l\(^{-1}\) FeSO\(_4\)·7H\(_2\)O/Na citrate 15 ml (from the solution of 7.5 g l\(^{-1}\) FeSO\(_4\) and 100 g l\(^{-1}\) sodium citrate), 0.015 g l\(^{-1}\) CaCl\(_2\)·2H\(_2\)O, 7.5 µg l\(^{-1}\) thiamine HCl, 0.04 mg ml\(^{-1}\) L-Phe, 0.04 mg ml\(^{-1}\) L-Tyr and 5 g l\(^{-1}\) l-Phe as sole carbon source [15]. Ampicillin sodium salt (100 mg l\(^{-1}\)) and/or kanamycin sulfate (50 mg l\(^{-1}\)) was added when appropriate.

Escherichia coli strains were grown in 250 ml shake flasks filled with 20 ml of medium at 37 °C with 150-rpm agitation. Overnight cultures were used as inocula (1% v/v). Induction was with 0.5 mM isopropyl-β-d-thiogalactopyranoside (IPTG, final concentration) at an OD of 600 nm (OD\(_{600}\)) of about 0.6. Samples were taken and centrifuged at 22,000g for 10 min. The supernatants were removed and stored at −20 °C until further use. The glycerol fed-batch cultivation was performed in 250 ml shake flasks with 20 ml media. The initial glycerol concentration was 5 g l\(^{-1}\). Cultures were inoculated with an overnight grown culture. After 24 h of cultivation, 0.5 mM IPTG (final concentration) was added to the cells and the shake flasks were transferred from 37 to 30 °C before starting to add ~5 g l\(^{-1}\) glycerol to the culture every 12 h until 84 h. Furthermore, every 24 h, 30 mM sodium bicarbonate was added to adjust the pH and 15 mM ammonium sulfate was added as ammonium source. Samples were taken and centrifuged at 22,000g for 10 min. The supernatants were removed and stored at −20 °C until use.
Fed-batch fermentation in a 30 l bioreactor
A 30 l stirred-tank reactor (Bioengineering, Wald, Switzerland) with a batch volume of 8 l and a final volume of 12.25 l was used and a minimal medium with glycerol as sole carbon source. The concentration of supplementation compounds was increased 1.5-fold, e.g. supplementation was with 60 mg l⁻¹ l-Phe, 60 mg l⁻¹ of l-Tyr. The concentration of antibiotics was kept at 100 mg l⁻¹ ampicillin sodium salt and 50 mg l⁻¹ kanamycin sulfate. The working conditions were pH 7.0 (controlled by the addition of 15% ammonia solution), 30% oxygen saturation with a reactor pressure of 500 hPa above atmospheric pressure (starting with pO₂ ~ 100% at 350 rpm with an aeration rate of 4 l min⁻¹; when reaching 30% oxygen saturation, the stirring rate was adjusted). A preculture (1.2 l grown in shake flasks with the same medium) which was in the exponential growth in shake flasks, was used to inoculate the fermentation (starting CDW ~ 0.18 g l⁻¹) t 37 °C. 11.75 h after inoculation IPTG (0.5 mM), l-Tyr (0.36 mM) and l-Phe (0.33 mM) were added and the temperature was shifted from 37 to 30 °C. The initial glycerol concentration was about 8.1 g l⁻¹. The glycerol feed was started after the initial glycerol was depleted (indicated by a rise in pO₂). Glycerol was fed to maintain a concentration between 0.6 and 1.0 g l⁻¹ during cultivation. If needed, antifoam agent (Struktol J647) from Schill Seilacher (Hamburg) was added to the culture. Additionally, l-Phe and l-Tyr were added in two pulses (34 h after inoculation 0.5 mM l-Phe and l-Tyr; 56 h after inoculation 0.3 mM l-Phe and l-Tyr) to allow biomass formation.

DNA manipulations
For plasmid constructions, E. coli strain DH5α was used. Standard molecular biology methods were applied [104]. DNA containing the genes papBC from S. venezuelae was custom synthesized (Thermo Fisher/GeneArt, Regensburg, Germany) and codon optimized for E. coli to give pMK-papBC (see Table 1); this plasmid DNA was then restricted with BglII and BamHI. A resulting fragment containing papBC was isolated and ligated with a BamHI restricted pC53 vector (based on pFI19 EH vector [44] which already carries the pabAB genes from C. glutamicum [41]) to obtain pC53BC (see Additional file 1: Figure S4). The recombinant genes are under the control of the lacF/P_{lac} promoter. The sequence and direction of papBC was verified by sequencing (GATC Biotech AG, Konstanz, Germany). Plasmid pJNT-arofBL is based on vector pJNT522 which in turn is derived from pLEM2 [58] and pFI119EH. Construction of pJNT522 vector is described in the Additional file 1. In brief, pJNT522 contains a fragment of pLEM2 plasmid carrying the mob region, origin of replication, and kanamycin resistance gene as well as the Ptac promoter, MCS and rnrB T1T2 terminator of transcription from the pJFI19EH vector. pJNT522 is compatible with pJFI19EH- derived plasmids. The subcloning of aroFB and aroL genes of E. coli and ligation on vector pJNT522 to yield pJNT-arofBL is described in the Additional file 1.

Deletion of tyrR gene from the E. coli chromosome
The deletion of the gene tyrR, encoding the regulator of the tyr regulon, was carried out according to a λ-red recombinase method [55]. A linear DNA fragment containing the FRT-flanked chloramphenicol resistance (cat) cassette was amplified from plasmid pCAS30-FRT-cat-FRT [57] using the primer pair DeltyrRFw/-Rw (see Table 1 for sequences). The thus obtained amplified linear DNA was introduced by electroporation into electrocompetent E. coli FUS4.7 cells that carried the Red recombinase expression vector pKD46 [55]. After confirmation of the FRT-cat-FRT integration by colony PCR with the primer pair Ko-tyrRFw/-Rw (see Table 1), the cat marker was removed by transient expression of a FLP recombinase from plasmid pCP20 [56] to eventually generate the TyrR deletion strain, FUS437R. Verification of the disruption was performed using colony PCR with primers up- and downstream of disrupted regions (Ko-tyrRFw/-Rw). Finally, cells were grown at 42 °C to remove the temperature-sensitive replicons, pCP20 or pKD46, respectively [55].

Analytical methods
Growth of E. coli cells was followed by measuring OD_{600} in a UV–vis spectrophotometer (Cary 50 Bio, Agilent Technologies). The formation of L-PAPA was routinely analyzed and quantified by high-performance liquid chromatography (HPLC, 1260 Infinity series, Agilent Technologies) with a diode array detector (1260 Infinity series, Agilent Technologies) at a wavelength of 210 nm. A Prontosil C18 column (250 × 4 mm, CS-Chromatographie Services GmbH, Langerwehe, Germany) was used for separation at 40 °C. The mobile phase containing 40 mM Na₂SO₄ (adjusted at pH ~ 2.7 with methane sulfonic acid) was used with a flow rate of 1 ml min⁻¹. Glycerol concentrations were determined by HPLC with a refractive index detector (1260 Infinity series, Agilent Technologies). An isocratic flow of 0.6 ml min⁻¹ of 5 mM H₂SO₄ was applied at 40 °C. The produced L-PAPA was analyzed by mass spectrometry. It was determined by using an Agilent 6130 mass spectrometer system with electron spray ionization (Agilent Technologies; Germany).
Additional files

**Additional file 1.** Construction and sequences of vectors

**Additional file 2.** Comparison of mass spectra of commercially available L-PAPA (A) with fermentatively produced L-PAPA from E. coli FU54-7R (pC53BC/pN Tara FlB) (B). The mass spectra were recorded with an Agilent 6130 mass spectrometer system with electron spray ionization in positive mode (Agilent Technologies; Germany). In both measurements the L-PAPA + H⁺ mass of 181 was detected.

Abbreviations

ADC: 4-amino-4-deoxychorismate; ADP: adenosine diphosphate; α-KG: α-ketoglutarate; Amp: ampicillin; ApSP: aspartate aminotransferase; AraB: dehydroquinase synthase; AraC: dihydroxyacetone phosphate; Arab: shikimate kinase; ATP: adenosine triphosphate; DAHP: 3-deoxy-d-arabino-heptulosonate 7-phosphate; DHAP: dihydroxyacetone phosphate; DHQ: dehydroquinate; E4P: erythrose-4-phosphate; F6P: fructose-6-phosphate; FBP: fructose-1,6-bisphosphate; G3P: glycerol-3-phosphate; GAP: glyceraldehyde-3-phosphate; GlpD: glycerol-3-phosphate dehydrogenase; GlpF: glycerol facilitator; GlpK: glycolate kinase; Glu: glucose; GluK: glutamine; Glx: glutamine; GlpX: fructose-1,6-bisphosphatase; IPTG: isopropyl-β-D-thiogalactopyranoside; Kan: kanamycin; PAPA: para-aminophenylnalanine; Phe: phenylalanine; Tet: tetracycline; Tyr: tyrosine; MQ: menaquinone; OD: optical density; PABA: para-aminobenzoate; PABA: para-aminobenzoate; PABAB: 4-amino-4-deoxychorismate synthase; PAG: para-aminoglutamate; PAG: para-aminoglutamate; PAP: 4-amino-4-deoxychorismate; PAPK: para-amino-p-hydroxyphenylpyruvate; PEP: phosphoenolpyruvate; PTS: PEP-dependent sugar:phosphotransferase system; TCA: tricarboxylic acid cycle; TktA: transketolase A; TyrB: aromatic aminotransferase; UQ: ubiquinone.

Authors' contributions

BMN, NT and JWW performed the experiments. BMN, GAS and JWW wrote the final manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors are grateful to Dr. Josef Altenbuchner (Institute of Industrial Genetics, University of Stuttgart) for providing the plasmid pJE M2 and to Dr. Bernd A. Nebel (Institute of Technical Biochemistry, University of Stuttgart) for helping with the MS measurements. We thank Ursula Degner (Research Center Jülich, Germany) for help with the cloning work leading to plasmids pF-109 and pF-112 and Alexander Dietrich (Institute of Biochemical Engineering, University of Stuttgart) for technical assistance with the bioreactor. We thank the Ministerium für Wissenschaft und Kunst Baden-Württemberg for financial support.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The dataset(s) supporting the conclusions of this article are all included within the article and Additional files.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

Behrouz Mohammad Nargesi was supported by a personal grant of the Ministry of Science, Research and Technology of Iran (MSRT, 91000277).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Gibson F, Jackman LM. Structure of chorismic acid, a new intermediate in aromatic biosynthesis. Nature. 1963;198:388–9.
2. Bongaarts J, Esser S, Lorbach V, Al-Momani L, Muller MA, Franke D, Grondal C, Kurutsch T, Bujnicki R, Takors R, et al. Diversity-oriented production of metabolites derived from chorismate and their use in organic synthesis. Angew Chem Int Ed Engl. 2011;50:7781–6.
3. Sprenger GA. From scratch to value: engineering Escherichia coli wild type cells to the production of L-phenylalanine and other fine chemicals derived from chorismate. Appl Microbiol Biotechnol. 2007;75:739–49.
4. Berry A. Improving production of aromatic compounds in Escherichia coli by metabolic engineering. Trends Biotechnol. 1996;14:250–6.
5. Noda S, Shirai T, Oyama S, Kondo A. Metabolic design of a platform Escherichia coli strain producing various chorismate derivatives. Metab Eng. 2016;33:119–29.
6. van Beilen JWA, Hellingwerf KJ. All three endogenous quinone species of Escherichia coli are involved in controlling the activity of the aerobic/anaerobic response regulator ArcA. Front Microbiol. 2016;7:1339.
7. Lee JH, Wendsch VF. Biotecnological production of aromatic compounds of the extended shikimate pathway from renewable biomass. J Biotechnol. 2017;257:211–21.
8. Young IG, Langman L, Luke RK, Gibson F. Biosynthesis of the iron-transport compound enterochelin: mutants of Escherichia coli unable to synthesize 2,3-dihydroxybenzoate. J Bacteriol. 1971;106:51–7.
9. Mene-Saffrane L, DellaPenna D. Biosynthesis, regulation and functions of tocopherol in plants. Plant Physiol Biochem. 2010;48:301–9.
10. Mast Y, Weber T, Goltz M, Orn-Winklauer R, Gondran A, Wohlfelben W, Schinko E. Characterization of the ‘pristinamycin supercluster’ of Streptomyces pristinaepralis. Microbiol Biotechnol. 2011;14:192–206.
11. Lin DR, Xiao MS, Zhao J, Li ZH, Xing BS, Li XD, Kong MZ, Li LY, Zhang Q, Liu YW, et al. An overview of plant phenolic compounds and their importance in human nutrition and management of type 2 diabetes. Molecules. 2016;21:1374.
12. Fernandez-Martinez LT, Bossetto C, Gomez-Escricrabo JP, Bipp MB, Al-Bassam MM, Chandra G, Bipp MJ. New insights into chloramphenicol biosynthesis in Streptomyces venezuelae ATCC 10712. Antimicrob Agents Chemother. 2014;58:7441–50.
13. Schuhmacher T, Loffler M, Hurler T, Takors R. Phosphat-dependent fed-batch processes: impact on carbon usage and energy metabolism in Escherichia coli. J Biotechnol. 2014;190:96–104.
14. Juminao D, Baidoo EE, Redding-Johanson AM, Bath TS, Burd H, Mukhopadhyay A, Petzold CJ, Keasling JD. Modular engineering of L-tyrosine production in Escherichia coli. Appl Environ Microbiol. 2012;78:889–98.
15. Gottlieb K, Albermann C, Sprenger GA. Improvement of L-phenylalanine production from glycerol by recombinant Escherichia coli strains: the role of extra copies of glpk, glpx, and knaE genes. Microbiol Cell Fact. 2014;13:96.
16. Ikeda M. Towards bacterial strains overproducing L-tyrosophan and other aromatics by metabolic engineering. Appl Microbiol Biotechnol. 2006;69:615–26.
17. Rodriguez A, Martinez JA, Flores N, Escalante A, Gosset G, Bolivar F. Engineering Escherichia coli to overproduce aromatic amino acids and derived compounds. Microb Cell Fact. 2014;13:126.
18. Weiner M, Trondele J, Albermann C, Sprenger GA, Weuser-Botz D. Metabolic control analysis of L-phenylalanine production from glycerol with engineered E. coli using data from short-term steady-state perturbation experiments. Biochem Eng J. 2017;126:86–100.
19. Min K, Park K, Park DH, Yoo YJ. Overview on the biotechnological production of L-DOPA. Appl Microbiol Biotechnol. 2015;99:575–84.
20. Cluis CP, Ekins A, Nacross L, Jiang H, Gold ND, Burja AM, Martin VJ. Identification of bottlenecks in Escherichia coli engineered for the production of CoQ10. Metab Eng. 2011;13:733–44.
21. Xu W, Yang S, Zhao J, Su T, Zhao L, Liu J. Improving coenzyme Q8 production in Escherichia coli employing multiple strategies. J Ind Microbiol Biotechnol. 2014;41:1297–303.
22. Kumar A, Tateyama S, Yasaki K, Ali MA, Takaya N, Singh R, Kaneko T. (1H-NMR and FT-IR dataset based structural investigation of polymeric acid s and polyimides from 4,4’-diaminostilbene. Data Brief. 2016;1:723–8.

23. Yamaguchi M, Saito R, Utsuki K, Ochiai A, Kawashima N, Tokuda Y, Katoh A. The nicotinic acid-p-aminophenylalanine-hydroxybenzoic acid triad induces apoptosis in human lung cancer U937 cells. Heterocycles. 2007;71:1503–8.

24. Masuo S, Zhou S, Kaneko T, Takaya N. Bacterial fermentation platform for producing artificial aromatic amines. Sci Rep. 2016;6:25764.

25. Suvannasara P, Tateyama S, Miyasato A, Matsumura K, Shimoda T, Ito T, Yamagata Y, Fujita T, Takaya N, Kaneko T. Biebed based polymers from 4-aminocinnamic acid photodimer. Macromolecules. 2014;47:1586–93.

26. Bergel F, Stock JA. Cyto active amino acid and peptide derivatives. I. Substituted phenylalanines. J Chem Soc. 1954. https://doi.org/10.1039/JR9540002409.

27. Jobdevairakkam C, Velledurai H. Process of making optically pure melphalan. WO2009171164A1. 2013.

28. Nollmann FI, Dauth C, Mulley G, Kegler C, Kaiser M, Waterfield NR, Bode HB. Molecular cloning of the plasmid RP4 primase region in a microbial photodimer. Biochem Biophys Res Commun. 1972;47:1360–5.

29. Martinez-Farina CF, Robertson AW, Yin HM, Monro S, McFarland SA, Cherepanov PP, Wackernagel W. Gene disruption in Escherichia coli and comparison with aspartate aminotransferase. Protein Sci. 1995;4:1743–9.

30. Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, Horn DM, Schultz PG. Generation of a bacterium with a 21 amino acid genetic code. J Am Chem Soc. 2003;125:935–9.

31. He J, Magarvey N, Piaire M, Vining LC. The gene cluster for chloramphenicol biosynthesis in Streptomyces venezuelae ISPS250 includes novel shikimate pathway homologues and a monomodular non-ribosomal peptide synthetase gene. Microbiology. 2001;147:2817–29.

32. Yanai K, Sumida N, Okakura K, Moriya T, Watanabe M, Murakami T. Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with Streptomyces venezuelae antibiotic biosynthetic genes. Nat Biotechnology. 2004;22:848–55.

33. Viswanathan VK, Green JM, Nichols BP. Kinetic characterization of phenylglycine biosynthetic genes involved in the biosynthesis of the 4-dimethylamino-4-deoxychorismate synthase. J Biotechnol. 2011;155:63–7.

34. Schaffer JR, Reck MR, Prasad NK, Wencewicz TA. Beta-Lactone formation during product release from a nonribosomal peptide synthetase. Nat Chem Biol. 2017;13:273–4.

35. Martinez-Farina CF, Robertson AW, Yin HM, Monro S, McFarland SA, Cherepanov PP, Wackernagel W. Gene disruption in Escherichia coli and comparison with aspartate aminotransferase. Protein Sci. 1995;4:1743–9.

36. Tateyama S, Masuo S, Suvannasara P, Oka Y, Miyazato A, Yasaki K, Teeratananond T, Muangsin N, Zhou SM, Kawasaki Y, et al. Ultrastrong, transparent polytruxillamides derived from microbial photodimers. Appl Microbiol Biotechnol. 2008;81:175–82.

37. Bongaerts J, Kramer M, Muller U, Raeven L, Wubbolts M. Metabolic engineering for microbial production of aromatic amino acids and derived 4-aminocinnamic acid photodimer. Macromolecules. 2014;47:1586–93.

38. Schaffer JR, Reck MR, Prasad NK, Wencewicz TA. Beta-Lactone formation during product release from a nonribosomal peptide synthetase. Nat Chem Biol. 2017;13:273–4.

39. Jobdevairakkam C, Velledurai H. Process of making optically pure melphalan. WO2009171164A1. 2013.

40. Nollmann FI, Dauth C, Mulley G, Kegler C, Kaiser M, Waterfield NR, Bode HB. Molecular cloning of the plasmid RP4 primase region in a microbial photodimer. Biochem Biophys Res Commun. 1972;47:1360–5.
66. Snell KD, Draths KM, Frost JW. Synthetic modification of the Escherichia coli chromosome: enhancing the biocatalytic conversion of glucose into aromatic chemicals. J Am Chem Soc. 1996;118:5605–14.
67. Li K, Frost JW. Synthesis of vanillin from glucose. J Am Chem Soc. 1998;120:10545–6.
68. Kunjapur AM, Tarasova Y, Prather KL. Synthesis and accumulation of aromatic aldehydes in an engineered strain of Escherichia coli. J Am Chem Soc. 2014;136:11644–54.
69. Balderas-Hernandez VE, Sabido-Ramos A, Silva P, Cabrera-Valladales N, Hernandez-Chavez G, Baez-Viveros JL, Martinez A, Bolivar F, Gosset G. Metabolic engineering for improving anthranilate synthesis from glucose in Escherichia coli. Microb Cell Fact. 2009;8:19.
70. Albermann C, Ghanegaonkar S, Lemuth K, Vallon T, Reuss M, Armbruster W, Sprenger GA. Biosynthesis of the vitamin E compound δ-tocotrienol in recombinant Escherichia coli cells. ChemBioChem. 2008;9:2524–33.
71. Kim B, Park H, Na D, Lee SY. Metabolic engineering of Escherichia coli for the production of phenol from glucose. Biotechnol J. 2014;6:261–9.
72. Magnus J. Method for producing phenol from renewable resources by fermentation. Patent WO 2014/076113 A1; 2013.
73. Miao L, Li Q, Diao A, Zhang X, Ma Y. Construction of a novel phenol synthetic pathway in Escherichia coli through 4-hydroxybenzoate decarboxylation. Appl Microbiol Biotechnol. 2015;99:5163–73.
74. Thompson B, Machas M, Nielsen DR. Engineering and comparison of non-natural pathways for microbial phenol production. Biotechnol Bioeng. 2016;113:1745–54.
75. Lin Y, Sun X, Yuan Q, Yan Y. Extending shikimate pathway for the production of muconic acid and its precursor salicylic acid in Escherichia coli. Metab Eng. 2014;23:62–9.
76. Koma D, Yamanaka H, Moriyoshi K, Ohmoto T, Sakai K. Production of aromatic compounds by metabolically engineered Escherichia coli with an expanded shikimate pathway. Appl Environ Microbiol. 2012;78:2033–16.
77. Vannelli T, Qi WW, Sweigard J, Gatenby AA, Sariaslani FS. Production of p-hydroxycinnamic acid from glucose in Saccharomyces cerevisiae and Escherichia coli by expression of heterologous genes from plants and fungi. Metab Eng. 2007;9:42–51.
78. McKenna R, Nielsen DR. Styrene biosynthesis from glucose by engineered E. coli. Metab Eng. 2011;13:544–54.
79. Noda S, Kondo A. Recent advances in microbial production of aromatic chemicals and derivatives. Trends Biotechnol. 2017;35:785–98.
80. Vargas-Tah A, Martinez LM, Hernandez-Chavez G, Rocha M, Martinez A, Bolivar F, Gosset G. Production of cinnamic and p-hydroxycinnamic acid from sugar mixtures with engineered Escherichia coli. Microb Cell Fact. 2015;14:6.
81. Satoh Y, Tajima K, Munekata M, Kusakabe K, Lee TS. Engineering of the shikimate pathway as an entry to aromatic second metabolism. Metab Eng. 2012;14:544–54.
82. Rodriguez AL, Trachtmann N, Becker J, Lohanatha AF, Biloten J, Boten CJ, Korneli C, Lima AOD, Porto LM, Sprenger GA, Wittmann C. Systems metabolic engineering of Escherichia coli for production of the antitumor drugs violaxin and deoxyviolaxin. Metab Eng. 2013;20:29–41.
83. Nakagawa A, Minami H, Kim JS, Koyanagi T, Katayama T, Sato F, Kumagai H. A bacterial platform for fermentative production of plant alkaloids. Nat Commun. 2011;2:526.
84. Nakagawa A, Matsumura E, Koyanagi T, Katayama T, Kawanou N, Yoshi matsu K, Yamamoto K, Kumagai H, Sato F, Minami H. Total biosynthesis of opiates by stepwise fermentation using engineered Escherichia coli. Nat Commun. 2016;7:10390.
85. Wang J, Shen X, Rej J, Xiu Q, Yan Y. Recent advances in microbial production of aromatic natural products and their derivatives. Appl Microbiol Biotechnol. 2018;102:47–61.
86. Kawaguchi H, Ogino C, Kondo A. Microbial conversion of biomass into bio-based polymers. Biosens Technol. 2017;245:1664–73.
87. Sprenger GA. Aromatic amino acids. In: Wendisch VF, editor. Amino acid biosynthesis—pathways, regulation and metabolic engineering. Berlin: Springer; 2007. p. 93–127 (Microbiology monographs).
88. Bailey JE. Toward a science of metabolic engineering. Science. 1991;252:1668–75.
89. Powell KS, Cooper PD, Forneck A. The biology, physiology and host-plant interactions of grape phylloxera Daktulosphaira vitifoliae. Behav Physiol Root Herbiv. 2013;45:159–218.
90. Koketsu K, Mitsuhashi S, Tabata K. Identification of homophenylalanine biosynthetic genes from the cyanobacterium Nostoc punctiforme PCC73102 and application to its microbial production by Escherichia coli. Appl Environ Microbiol. 2013;79:2201–8.
91. Muenoz AJ, Hernandez-Chavez G, de Anda R, Martinez A, Bolivar F, Gosset G. Metabolic engineering of Escherichia coli for improving l-3,4-dihydroxyphenylalanine (l-DOPA) synthesis from glucose. J Ind Microbiol Biotechnol. 2011;38:1845–52.
92. Wei T, Cheng BY, Liu JZ. Genome engineering Escherichia coli for L-DOPA overproduction from glucose. Sci Rep. 2016;6:30082.
93. Escalante A, Salinas Cervantes A, Gosset G, Bolivar F. Current knowledge of the Escherichia coli phosphoenolpyruvate-carbohydrate phosphotransferase system: peculiarities of regulation and impact on growth and product formation. Appl Microbiol Biotechnol. 2012;94:1483–94.
94. Herrmann KM. The shikimate pathway as an entry to aromatic second metabolism. Plant Physiol. 1995;107:7–12.
95. Andersen KB, von Meyenburg K. Are growth rates of Escherichia coli deregulated strains of Escherichia coli for L-DOPA production of aromatic natural products and their derivatives. Appl Microbiol Biotechnol. 2011;38:1845–52.
96. Collado-Vides J, Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.